| | CEOP/IVE/GDP (N = 51) | CEOP (N = 51) |
|---|
| Age (years; median IQR) | 56 (46.0–64.0) | 60 (52.0–65.0) |
| ≤ 60 years | 33 (65%) | 28 (55%) |
| > 60 years | 18 (35%) | 23 (45%) |
| Gender |
| Male | 34 (67%) | 32 (63%) |
| Female | 17 (33%) | 19 (37%) |
| Ann Arbor Stage |
| I–II | 10 (20%) | 9 (18%) |
| III–IV | 41 (80%) | 42 (82%) |
| B symptoms |
| Absent | 26 (51%) | 23 (45%) |
| Present | 25 (49%) | 28 (55%) |
| Performance status |
| 0–1 | 46 (90%) | 42 (82%) |
| 2 | 5 (10%) | 9 (18%) |
| Serum LDH |
| Normal | 25 (49%) | 28 (55%) |
| Elevated | 26 (51%) | 23 (45%) |
| EBV-DNA |
| Undetectable | 35/45 (78%) | 30/42 (71%) |
| Detectable | 10/45 (22%) | 12/42 (29%) |
| Extra-nodal involvement |
| 0–1 | 34 (67%) | 30 (59%) |
| ≥ 2 | 17 (33%) | 21 (41%) |
| Extra-nodal site |
| Skin | 4 (8%) | 5 (10%) |
| Gastrointestinal tract | 5 (10%) | 7 (14%) |
| Liver | 4 (8%) | 2 (4%) |
| Spleen | 14 (27%) | 14 (27%) |
| Lung | 2 (4%) | 3 (6%) |
| Bone marrow | 15 (30%) | 21 (41%) |
| Bone | 5 (10%) | 8 (16%) |
| Breast | 0 | 1 (2%) |
| IPI |
| 0–1 | 14 (27%) | 16 (31%) |
| 2–3 | 30 (59%) | 26 (51%) |
| 4–5 | 7 (14%) | 9 (18%) |
- Data are median (IQR), n (%), or n/N (%). CEOP cyclophosphamide, epirubicin, vincristine, and prednisone, IVE ifosmide, epirubicin, and etoposide, GDP gemcitabine, cisplatin, and dexamethasone, LDH lactate dehydrogenase, IPI International Prognostic Index
